Page 84 - Read Online
P. 84
Pippione et al. Steroidogenic enzymes in prostate cancer
A
B
C
D
Figure 17: Selected compounds that act as: (A) NTD modulators; (B) DBD inhibitors; (C) indirect inhibitors of AR and AR variants; and
(D) selective androgen receptor downregulator (SARD) compounds. AR: androgen receptor; DBD: DNA-binding domain; NTD: N-terminal
domain
model castration-resistant PCa cell line resistant to tumour strategy in the context of AR mutations
enzalutamide. These results suggest that selective AR that confer resistance to second-generation AR
degradation may be an effective therapeutic prostate antagonists [156] .
352 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 12, 2017
